Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Soft Tissue Sarcoma Pipeline Insight 2025' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the Soft Tissue Sarcoma Marketed and Pipeline Drugs profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Soft Tissue Sarcoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Soft Tissue Sarcoma Pipeline Outlook
Key Takeaways from the Soft Tissue Sarcoma Marketed and Pipeline Drugs Report
In May 2025, Adcendo ApS announced a Phase 1/2 study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma.
In May 2025, ImmunoGenesis conducted a study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma. TH-302 is activated at lower oxygen concentrations than other bioreductive prodrugs (Duan 2008) and tirapazamine, a hypoxic cytotoxin that has been extensively studied in both preclinical and clinical studies.
In May 2025, Epizyme Inc. organized a study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue.
DelveInsight's Soft Tissue Sarcoma Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Soft Tissue Sarcoma treatment.
The leading Soft Tissue Sarcoma Companies such as Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others.
Promising Soft Tissue Sarcoma Pipeline Therapies such as Bevacizumab [Avastin], MGCD516, Pazopanib Hydrochloride, Liposomal Vincristine, AdAPT-001, Rubitecan, Ridaforolimus, OMBRABULIN (AVE8062), and others.
Stay ahead with the most recent pipeline outlook for Soft Tissue Sarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Soft Tissue Sarcoma Treatment Drugs
Soft Tissue Sarcoma Emerging Drugs Profile
Fibronum + Doxorubicin: Philogen S.p.A.
Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications.) The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Currently, the drug is in Phase III stage of its development for the treatment of Soft Tissue Sarcoma.
Chiauranib: Chipscreen Biosciences, Ltd
Chiauranib, a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor, was developed by Chipscreen Biosciences specifically to address drug resistance. Chiauranib exerts a comprehensive anti-tumor effect by a triple-pathway mechanism that simultaneously inhibits tumor angiogenesis, prevents tumor cell mitosis, and modulates the tumor microenvironment. With a favorable safety profile, Chiauranib has outperformed drugs with a similar mechanism in its pharmacodynamic activity in animal studies.Currently, the drug is in Phase II stage of its development for the treatment of Soft Tissue Sarcoma.
LVGN6051 and Anlotinib: Lyvgen Biopharma Holdings Limited
Exlinkibart (LVGN6051) is a Anti-CD137/4-1BB agonistic monoclonal antibody and xLinkAb conditional 4-1BB agonistic monoclonal antibody with selective Fcγ-receptor IIB binding for targeted immune activation in the tumor microenvironment. LVGN6051 has achieved RP2D of 4 mg/kg Q3W, showing desirable PK and PD properties, acceptable safety profile and durable objective responses in heavily pre-treated patients with various solid tumors. Upon administration, anti-CD137 agonistic antibody LVGN6051 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. Registration clinical trials of exlinkibart in melanoma, sarcoma and head and neck cancers are planned. Currently, the drug is in Phase I/II stage of its development for the treatment of Soft Tissue Sarcoma.
The Soft Tissue Sarcoma Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Soft Tissue Sarcoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Soft Tissue Sarcoma Treatment.
Soft Tissue Sarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Soft Tissue Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Soft Tissue Sarcoma market
Explore groundbreaking therapies and clinical trials in the Soft Tissue Sarcoma Pipeline. Access DelveInsight's detailed report now! @ New Soft Tissue Sarcoma Drugs
Soft Tissue Sarcoma Companies
Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others.
Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Soft Tissue Sarcoma Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Unveil the future of Bronchiectasis Treatment. Learn about new Soft Tissue Sarcoma Marketed and Drugs Developments, and key companies with DelveInsight's expert analysis @ Bronchiectasis Market Drivers and Barriers
Scope of the Soft Tissue Sarcoma Pipeline Report
Coverage- Global
Soft Tissue Sarcoma Companies- Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others.
Soft Tissue Sarcoma Pipeline Therapies- Bevacizumab [Avastin], MGCD516, Pazopanib Hydrochloride, Liposomal Vincristine, AdAPT-001, Rubitecan, Ridaforolimus, OMBRABULIN (AVE8062), and others.
Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Soft Tissue Sarcoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Soft Tissue Sarcoma Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Soft Tissue Sarcoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Soft Tissue Sarcoma – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Fibronum + Doxorubicin: Philogen S.p.A.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Chiauranib: Chipscreen Biosciences, Ltd
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
LVGN6051 and Anlotinib: Lyvgen Biopharma Holdings Limited
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Soft Tissue Sarcoma Key Companies
Soft Tissue Sarcoma Key Products
Soft Tissue Sarcoma- Unmet Needs
Soft Tissue Sarcoma- Market Drivers and Barriers
Soft Tissue Sarcoma- Future Perspectives and Conclusion
Soft Tissue Sarcoma Analyst Views
Soft Tissue Sarcoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
31 minutes ago
- Globe and Mail
Septic System Owners Are Ditching the Old Way of Cleaning Toilets
You're already cleaning your toilet — why not clean your septic system too, with the same flush? The first and only 2-in-1 cleaner that cleans your toilet and treats your septic system at the same time. Instead of using harsh chemicals that can harm septic health, this foaming formula uses Dr. Pooper's proven Accelerator by Dr. Pooper® bio-technology to safely break down septic solids. Hockley, TX - Jun 3, 2025 - In a market filled with 'single-purpose' bathroom cleaners, the new Accelerator by Dr. Pooper® Toilet Bowl & Septic Cleaner is simplifying routines — and septic system maintenance — with a smarter, dual-function approach. What makes this product so different? It's the first and only 2-in-1 cleaner that cleans your toilet and treats your septic system at the same time. Instead of using harsh chemicals that can harm septic health, this foaming formula uses Dr. Pooper's proven Accelerator by Dr. Pooper® bio-technology to safely break down solids in your pipes, tank, and drain field. 'It's the easiest and most effective septic maintenance you'll ever do,' said Chris Denny, CEO and co-founder of Dr. Pooper. 'You're already cleaning your toilet — why not clean your septic system too, with the same flush?' The 2-in-1 Toilet Bowl & Septic Cleaner has quickly become a favorite among homeowners with septic systems, especially those looking to: And because it's totally non-toxic, there's no risk to pets, kids, or groundwater. The 2-in-1 Toilet Bowl & Septic Cleaner is available now on Media Contact Company Name: Dr. Pooper Enterprise LLC Contact Person: Chris Denny Email: Send Email Phone: 8323016075 Address: 27122 FM 2920 City: Hockley State: Texas Country: United States Website:
Globe and Mail
31 minutes ago
- Globe and Mail
FTI Consulting: A Hidden Gem or Just Fine?
Explore the exciting world of FTI Consulting (NYSE: FCN) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of April 28, 2025. The video was published on Jun. 3, 2025. Should you invest $1,000 in FTI Consulting right now? Before you buy stock in FTI Consulting, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and FTI Consulting wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor 's total average return is987% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
Globe and Mail
an hour ago
- Globe and Mail
Toronto-based toy maker Spin Master cuts jobs as it weathers tariff impacts
Toy maker Spin Master Corp. TOY-T says it has cut jobs across the company as it tries to weather the impact of global tariffs on its business. In an e-mailed statement, spokeswoman Tammy Smitham did not say how many employees were affected. She says the layoffs were one part of a multi-pronged plan to deal with the effect of tariffs, which also includes diversifying its supply chains and cutting costs. Spin Master said last month that U.S. tariffs on countries where it produces toys, especially China, have made forecasts so challenging that it withdrew its guidance for the remainder of the year. The company behind the Hatchimals, Gabby's Dollhouse and Monster Jam brands has said it aims to drastically reduce its reliance on China for production over the next two years. In February, Spin Master said it had decided to wind down a games studio in Sweden as the cost to acquire new users weighed too heavily on revenue.
